350 related articles for article (PubMed ID: 17080234)
21. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
22. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
23. Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities.
Artinyan A; Kim J; Soriano P; Chow W; Bhatia S; Ellenhorn JD
Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2194-201. PubMed ID: 18708414
[TBL] [Abstract][Full Text] [Related]
24. Gastric GISTs. Personal experience.
Mingolla GP; Riccio PA; Linguerri R; La Donna M; Zannelli M; Artuso S
Ann Ital Chir; 2007; 78(4):283-8; discussion 288-9. PubMed ID: 17990602
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
Jpn J Clin Oncol; 2006 Nov; 36(11):704-11. PubMed ID: 17068083
[TBL] [Abstract][Full Text] [Related]
26. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
[TBL] [Abstract][Full Text] [Related]
27. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate.
Rutkowski P; Nowecki Z; Nyckowski P; Dziewirski W; Grzesiakowska U; Nasierowska-Guttmejer A; Krawczyk M; Ruka W
J Surg Oncol; 2006 Mar; 93(4):304-11. PubMed ID: 16496358
[TBL] [Abstract][Full Text] [Related]
28. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
Eisenberg BL; Judson I
Ann Surg Oncol; 2004 May; 11(5):465-75. PubMed ID: 15123459
[TBL] [Abstract][Full Text] [Related]
29. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
Dematteo RP; Gold JS; Saran L; Gönen M; Liau KH; Maki RG; Singer S; Besmer P; Brennan MF; Antonescu CR
Cancer; 2008 Feb; 112(3):608-15. PubMed ID: 18076015
[TBL] [Abstract][Full Text] [Related]
30. Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: report of a case.
Ando Y; Tsunoda T; Beck Y; Takayama T; Tahara H
Surg Today; 2005; 35(2):157-60. PubMed ID: 15674500
[TBL] [Abstract][Full Text] [Related]
31. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
Zhu J; Wang Y; Hou M; Li HY; Zhang J
Oncology; 2007; 73(5-6):324-7. PubMed ID: 18497504
[TBL] [Abstract][Full Text] [Related]
32. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease.
An JY; Choi MG; Noh JH; Sohn TS; Kang WK; Park CK; Kim S
Eur J Surg Oncol; 2007 Oct; 33(8):1030-5. PubMed ID: 17428635
[TBL] [Abstract][Full Text] [Related]
33. Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience.
Armbrust T; Sobotta M; Gunawan B; Füzesi L; Langer C; Cameron S; Ramadori G
Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):819-23. PubMed ID: 19369884
[TBL] [Abstract][Full Text] [Related]
34. Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
Jakob J; Mussi C; Ronellenfitsch U; Wardelmann E; Negri T; Gronchi A; Hohenberger P
Ann Surg Oncol; 2013 Feb; 20(2):586-92. PubMed ID: 22965573
[TBL] [Abstract][Full Text] [Related]
35. [GIST: our experience].
Rossi MT; Fasano G; Morlino A; Scutari F
G Chir; 2009; 30(1-2):41-5. PubMed ID: 19272232
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).
Bauer S; Rutkowski P; Hohenberger P; Miceli R; Fumagalli E; Siedlecki JA; Nguyen BP; Kerst M; Fiore M; Nyckowski P; Hoiczyk M; Cats A; Casali PG; Treckmann J; van Coevorden F; Gronchi A
Eur J Surg Oncol; 2014 Apr; 40(4):412-9. PubMed ID: 24491288
[TBL] [Abstract][Full Text] [Related]
37. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
Griffin JM; Amand MS; Demetri GD
Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of gastrointestinal stromal tumors with imatinib mesylate: a center-based study of 13 patients].
Bar-Sela G; Lev LM; Kuten A; Wollner M; Haim N
Harefuah; 2006 Jan; 145(1):2-7, 80. PubMed ID: 16450715
[TBL] [Abstract][Full Text] [Related]
39. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
40. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
